WEC
ALNY icon

Winslow Evans & Crocker’s Alnylam Pharmaceuticals ALNY Stock Holding History

Winslow Evans & Crocker’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$167K Buy
1,285
+185
+17% +$24.7K 0.03% 357
2020
Q3 		$160K Sell
1,100
-300
-21% -$42.6K 0.04% 297
2020
Q2 		$207K Hold
1,400
– – 0.06% 268
2020
Q1 		$154K Hold
1,400
– – 0.05% 268
2019
Q4 		$162K Hold
1,400
– – 0.04% 311
2019
Q3 		$114K Sell
1,400
-60
-4% -$4.75K 0.03% 369
2019
Q2 		$106K Hold
1,460
– – 0.03% 388
2019
Q1 		$138K Sell
1,460
-50
-3% -$4.18K 0.04% 328
2018
Q4 		$112K Sell
1,510
-200
-12% -$15.4K 0.04% 337
2018
Q3 		$150K Hold
1,710
– – 0.05% 302
2018
Q2 		$170K Buy
1,710
+250
+17% +$24.8K 0.05% 285
2018
Q1 		$174K Hold
1,460
– – 0.06% 273
2017
Q4 		$185K Buy
1,460
+60
+4% +$7.54K 0.06% 270
2017
Q3 		$164K Sell
1,400
-35
-2% -$2.99K 0.05% 285
2017
Q2 		$114K Sell
1,435
-1
-0.1% -$64 0.03% 412
2017
Q1 		$73.5K Buy
1,436
+250
+21% +$11.6K 0.02% 462
2016
Q4 		$44.4K Buy
1,186
+136
+13% +$5.69K 0.01% 561
2016
Q3 		$71.2K Hold
1,050
– – 0.02% 469
2016
Q2 		$58.3K Hold
1,050
– – 0.02% 481
2016
Q1 		$65.9K Hold
1,050
– – 0.02% 446
2015
Q4 		$98.8K Hold
1,050
– – 0.03% 396
2015
Q3 		$84.4K Hold
1,050
– – 0.03% 416
2015
Q2 		$126K Hold
1,050
– – 0.04% 383
2015
Q1 		$110K Hold
1,050
– – 0.03% 410
2014
Q4 		$102K Sell
1,050
-100
-9% -$9.27K 0.03% 411
2014
Q3 		$89.8K Hold
1,150
– – 0.03% 442
2014
Q2 		$72.6K Sell
1,150
-100
-8% -$5.94K 0.02% 433
2014
Q1 		$83.9K Hold
1,250
– – 0.03% 394
2013
Q4 		$80K Buy
+1,250
New +$74.6K 0.03% 427

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Winslow Evans & Crocker's ALNY Position: Q4 2020 in Review

Winslow Evans & Crocker increased its Alnylam Pharmaceuticals (ALNY) stake by 17% in Q4 2020, buying an estimated $24.7K and bringing the position to 1,285 shares worth $167K. The position accounts for 0.03% of the portfolio, ranked #357.

Winslow Evans & Crocker first reported a position in ALNY in Q4 2013 and has held it in 29 quarters since. The position peaked at $207K in Q2 2020. 374 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • Winslow Evans & Crocker held 1,285 shares of Alnylam Pharmaceuticals worth $167K as of Q4 2020.
  • Winslow Evans & Crocker bought 185 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $24.7K.
  • Alnylam Pharmaceuticals made up 0.03% of Winslow Evans & Crocker's portfolio in Q4 2020, its #357 holding.
  • Winslow Evans & Crocker first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 29 quarters since.
  • Winslow Evans & Crocker's Alnylam Pharmaceuticals position peaked at $207K in Q2 2020.
  • 374 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.